WSD0922-FU

DRUG3 trials

Sponsors

Wayshine Biopharm Inc., Wayshine Biopharm, Inc.

Conditions

EGFR Mutation Positive Advanced Non-Small Cell Lung CancerNon Small Cell Lung Cancer (NSCLC)Non-Small Cell Lung Cancer

Phase 1

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

RecruitingNCT06631989

Wayshine Biopharm, Inc.EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

Start: 2024-09-04End: 2027-12-31Target: 100Updated: 2025-08-29

A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC

RecruitingNCT07206498

Wayshine Biopharm, Inc.Non Small Cell Lung Cancer (NSCLC)

Start: 2025-10-17End: 2029-10-14Target: 48Updated: 2025-11-28

Phase 2

A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene

RecruitingCTIS2024-519713-65-00

Wayshine Biopharm Inc.Non-Small Cell Lung Cancer

Start: 2025-09-04Target: 10Updated: 2025-11-17

Related Papers

A multicenter, open-label, single-arm phase I/II study to assess the efficacy and safety of WSD0922-FU in patients with EGFR C797Sm+ advanced non-small cell lung cancer (NSCLC) in China (NCT06631989).

Journal of Clinical Oncology2025-05-28